Although carbohydrates are a principal component of the human diet, the mechanism of the final stages of starch digestion is not fully understood. One approach to treating metabolic diseases such as type II diabetes, obesity, and congenital sucrase isomaltase deficiency is inhibition of intestinal α-glucosidases and pancreatic α-amylases. Intestinal α-glucosidases, sucrase isomaltase (SI) and maltase glucoamylase (MGAM), are responsible for the final step of starch hydrolysis in mammals: the release of free glucose. MGAM and SI consist of two catalytic subunits: N-terminal and C-terminal, with overlapping, but variant substrate specificities. The objective of this thesis is to increase the understanding of the differential substrate specificity seen in the catalytic subunits of SI and MGAM. Through inhibitor studies, the structural and biochemical differences between the enzymatic subunits are explored, illustrating that each individual catalytic subunit can be selectively inhibited. In Chapter 3, homology models of ctSI and ctMGAM-N20 are presented, giving insight into the residues hypothesized to impact substrate specificity, enhancing our understanding of the functionality of these enzymatic subunits and overlapping substrate specificity. The structural implications of mutations seen in ntSI in CSID patients and the potential functional and structural implications are discussed in Chapter 4 in addition to the prevalence of SNPs in the SI gene in different populations. The mammalian α-glucosidases are compared to the 3 Å structure of CfXyl31, a Family 31 glycoside hydrolase from Cellulomonas fimi. Comparison to Family 31 glycoside hydrolases of known structure gives rise to possible mutations proposed to mimic ntMGAM α-glucosidase activity. Through inhibitor studies, homology models, examining mutations found in disease states such as congenital sucrase isomaltase deficiency, and investigating a bacterial family 31 glycoside hydrolase from Cellulomonas fimi, the active site characteristics and substrate specificities of SI and MGAM are better understood.

No description available.

No description available.

Human maltase-glucoamylase (MGAM) and sucrase-isomaltase (SI) are the small-intestinal glucosidases responsible for catalyzing the last glucose-releasing step in starch digestion. MGAM and SI are each composed of duplicated catalytic domains, N- and C-terminal, which display complementary substrate specificities for the mixture of short linear and branch oligosaccharide substrates that typically make up terminal starch digestion products. As MGAM and SI are involved in post-prandial glucose production, regulating their activities with α-glucosidase inhibitors is an attractive approach to controlling blood glucose levels for the prevention and treatment of Type 2 diabetes. To better understand the complementary activities and mechanism of inhibition of these intestinal glucosidases, this thesis aims to characterize the individual N- and C-terminal MGAM and SI domains using a combination of X-ray crystallographic structural studies, enzyme kinetics, and inhibitor studies. First, the structure of the N-terminal domain of MGAM (ntMGAM) was determined in its apo form and in complex with the inhibitor acarbose. In addition to sequence alignments and kinetics studies, the structures provide insight into the preference of the N-terminal MGAM domain for short linear substrates and the C-terminal domain for longer substrates. Second, the structure of ntMGAM was determined in complex with various α-glucosidase inhibitors, including those currently on the market (acarbose and miglitol), a new class of inhibitors from natural extracts of Salacia reticulata (salacinol, kotalanol and de-O-sulfonated kotalanol) and chemically synthesized derivatives of salacinol. These studies reveal the features of the Salacia reticulata inhibitors that are essential for inhibitory activity and highlight their potential as future drug candidates. Third, the crystal structure of the N-terminal domain of SI (ntSI) was determined in apo-form and in complex with kotalanol. Structural comparison of ntSI and ntMGAM reveal key differences in active site architectures, which are proposed to confer differential substrate specificity.

Human maltase-glucoamylase (MGAM) and sucrase-isomaltase (SI) are the small-intestinal glucosidases responsible for catalyzing the last glucose-releasing step in starch digestion. MGAM and SI are each composed of duplicated catalytic domains, N- and C-terminal, which display complementary substrate specificities for the mixture of short linear and branch oligosaccharide substrates that typically make up terminal starch digestion products. As MGAM and SI are involved in post-prandial glucose production, regulating their activities with α-glucosidase inhibitors is an attractive approach to controlling blood glucose levels for the prevention and treatment of Type 2 diabetes. To better understand the complementary activities and mechanism of inhibition of these intestinal glucosidases, this thesis aims to characterize the individual N- and C-terminal MGAM and SI domains using a combination of X-ray crystallographic structural studies, enzyme kinetics, and inhibitor studies. First, the structure of the N-terminal domain of MGAM (ntMGAM) was determined in its apo form and in complex with the inhibitor acarbose. In addition to sequence alignments and kinetics studies, the structures provide insight into the preference of the N-terminal MGAM domain for short linear substrates and the C-terminal domain for longer substrates. Second, the structure of ntMGAM was determined in complex with various α-glucosidase inhibitors, including those currently on the market (acarbose and miglitol), a new class of inhibitors from natural extracts of Salacia reticulata (salacinol, kotalanol and de-O-sulfonated kotalanol) and chemically synthesized derivatives of salacinol. These studies reveal the features of the Salacia reticulata inhibitors that are essential for inhibitory activity and highlight their potential as future drug candidates. Third, the crystal structure of the N-terminal domain of SI (ntSI) was determined in apo-form and in complex with kotalanol. Structural comparison of ntSI and ntMGAM reveal key differences in active site architectures, which are proposed to confer differential substrate specificity.

The aim of this study was to determine the mean lethal concentration (96 h) for waterborne copper (LC50), as well as the effect of the exposure to copper on growth, metabolic parameters (glycogen, glucose, lactate, and protein) in some tissues, activity of acetylcholinesterase (AChE) (brain and muscle), amylase and maltase (intestine) in silver catfish (Rhamdia quelen). The LC50 for copper was 0.4 mg/L. On growth experiments fish were exposed to 10 and 20% LC50, i.e., 0.04 and 0.08 mg/L respectively. Exposure to copper did not change growth parameters (weight, length and biomass). In the liver, lactate levels increased in juveniles exposed to 0.04 mg/L and decreased in those maintained at 0.08 mg/L, while protein levels decreased in those exposed to both concentrations compared to unexposed specimens. Glycogen levels in the muscle were lower in fish exposed to both concentrations, glucose and lactate were higher in those exposed to 0.04 mg/L and decreased in juveniles maintained at 0.08 mg/L, while protein was higher in those exposed to 0.08 mg/L. Glucose and lactate plasma levels were higher in juveniles exposed to 0.04 mg/L, but protein levels were lower in those maintained at both copper concentrations. Amylase activity was lower in juveniles exposed to both concentrations, but maltase was higher in those exposed to 0.04 mg/L than control group. Brain AChE activity was lower in fish exposed to both concentrations while muscle AChE activity was not affected after 45 days of exposure. It can be concluded that copper can change several metabolic parameters and enzymes of toxicological and feeding interest even at sublethal concentrations. / O objetivo deste estudo foi verificar a concentração letal média em 96 h (CL50) para o cobre, bem como o efeito da exposição ao cobre sobre o crescimento, parâmetros metabólicos (glicogênio, glicose, lactato e proteína) em alguns tecidos (fígado, músculo e cérebro) e a atividade da acetilcolinesterase (AChE) (cérebro e músculo), amilase e maltase (intestino) em jundiás (Rhamdia quelen.). A CL50 para o cobre foi 0,4 mg/L. Nos experimentos de crescimento os peixes foram expostos durante 45 dias a 10 e 20% da CL50, ou seja, 0,04 e 0,08 mg/L respectivamente. A adição de cobre não alterou os parâmetros de crescimento avaliados (peso, comprimento e biomassa). No fígado, os níveis de lactato aumentaram nos exemplares expostos a 0,04 mg/L e diminuíram nos mantidos em 0,08 mg/L, enquanto que os níveis de proteína diminuíram em ambas as concentrações em relação ao grupo controle. No músculo houve redução na atividade do glicogênio nos exemplares mantidos nas duas concentrações testadas, a glicose e o lactato aumentaram nos expostos a 0,04 mg/L e diminuíram nos expostos a 0,08 mg/L, e a proteína aumentou nos mantidos em 0,08 mg/L. Os níveis de glicose e lactato no plasma foram maiores nos exemplares mantidos em 0,04 mg/L e diminuíram os níveis de proteína nos expostos a ambas as concentrações de cobre. A atividade da amilase foi menor nos juvenis expostos a ambas as concentrações, enquanto a da maltase foi maior em 0,04 mg/L quando comparada ao grupo controle. A atividade da AChE cerebral foi menor nos exemplares expostos a ambas concentrações, enquanto que a AChE muscular não sofreu alterações após os 45 dias de exposição. Conclui-se que o cobre mesmo em concentrações subletais pode alterar diversos parâmetros metabólicos e enzimas de interesse toxicológico e alimentar.

Acid maltase deficiency (AMD) is a rare autosomal recessive genetic disorder that results in an accumulation of glycogen in the lysosomal storage vacuoles. It is classified as a glycogen storage disease (type II) and is also known as Pompe's disease. The prognosis of the patient with AMD is poor and the main cause of death is respiratory failure. We report a female patient whose respiratory insufficiency was documented to occur most severely during rapid eye movement sleep and who benefited clinically from the institution of nocturnal noninvasive bilevel positive airway pressure.